Vivos Therapeutics, Inc. (VVOS)
| Market Cap | 16.57M |
| Revenue (ttm) | 14.50M |
| Net Income (ttm) | -15.41M |
| Shares Out | 1.33M |
| EPS (ttm) | -13.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 105,435 |
| Open | 12.56 |
| Previous Close | 12.56 |
| Day's Range | 11.93 - 12.83 |
| 52-Week Range | 2.73 - 74.05 |
| Beta | 8.76 |
| Analysts | Strong Buy |
| Price Target | 62.50 (+402.41%) |
| Earnings Date | Nov 14, 2023 |
About VVOS
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment alternatives for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and... [Read more]
Financial Performance
In 2022, VVOS's revenue was $16.02 million, a decrease of -5.10% compared to the previous year's $16.89 million. Losses were -$23.85 million, 17.5% more than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for VVOS stock is "Strong Buy" and the 12-month stock price forecast is $62.5.
News
Vivos Therapeutics Presents Groundbreaking Event: “Empowering Women to Champion Airway”
Vivos unites influential women leaders in medicine and dentistry to drive collaboration following first ever FDA 510(k) clearance of an oral device to treat severe OSA Vivos unites influential women l...
Black Swan: this small cap surged over 1000% last week
Every so often, a move occurs in the stock market that can best be described as a 'black swan.' That is to say, a move that occurs in an individual stock that is exceedingly rare from a probabilistic ...
Vivos Therapeutics' stock soars as sleep apnea device gets regulatory clearance
Vivos Therapeutics Inc. shares VVOS jumped more than 270% Wednesday after the medical-device maker got regulatory clearance for removable oral appliances that treat obstructive sleep apnea.
US FDA clears Vivos Therapeutics' oral device treatment for sleep apnea
Vivos Therapeutics said on Wednesday the U.S. health regulator has cleared its oral device treatment for severe obstructive sleep apnea (OSA).
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral Device Treatment of Severe Obstructive Sleep Apnea
With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos With this unprec...
Vivos Therapeutics Reports Third Quarter 2023 Financial Results and Provides Operational Update
Operating Expenses Decreased 32% Year Over Year and 19% Sequentially as Cost Cutting Measures Take Hold New Strategic Relationships, Including U.S. Nationwide Distribution Agreement with Lincare, Expe...
Vivos Therapeutics Schedules Release of Third Quarter 2023 Financial Results and Conference Call
LITTLETON, Colo., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for pat...
Vivos Therapeutics Closes $4 Million Private Placement
LITTLETON, Colo., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing innovative treatments for pat...
Vivos Therapeutics Announces Reverse Stock Split
1-for-25 reverse stock split to become effective as of the opening of trading tomorrow, October 27, 2023 1-for-25 reverse stock split to become effective as of the opening of trading tomorrow, October...
Vivos Therapeutics Signs Nationwide Distribution Agreement with Lincare
Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement Lincare to distribute Vivos oral appliances through an exclusive nationwide agreement
Vivos Therapeutics to Begin Clinical Trial at Stanford Medicine
Randomized controlled clinical trial using Vivos' DNA Oral Appliance Therapy to study the DNA's impact on OSA versus CPAP Randomized controlled clinical trial using Vivos' DNA Oral Appliance Therapy t...
Vivos Therapeutics Announces Strategic Collaboration in the Middle East-North Africa Region to Support International Expansion
Vivos Executes Distribution Agreement with Established Dubai-based Sleep Testing Company Subject to Regulatory Approvals, Vivos Could See Revenue From This Collaboration in 2024 LITTLETON, Colo., Oct....
Vivos Therapeutics Executes Strategic Agreements with Ormco and On Demand Orthodontist To Provide Spark™ Clear Aligners to Its National Network of Providers
New Relationships Expected to Add Potentially Significant New Revenue Opportunities for Vivos as well as Airway-Focused Expertise and Potential Cost Savings for Vivos-trained Providers New Relationshi...
New York Times Best-Selling Author James Nestor to Headline List of Speakers for Fifth Annual Vivos Breathing Wellness Conference
Vivos Attracts Wide Group of Experts in Dental and Medical Disciplines With a Shared Vision to Treat the Millions of Patients Suffering with Breathing-Related Sleep Disorders Vivos Attracts Wide Group...
Vivos Therapeutics Reports Second Quarter 2023 Financial Results and Provides Operational Update
Operating Expenses Decreased 31% Quarter Over Quarter and 25% Year to Date, Reflecting Cost Cutting Initiatives
Vivos Therapeutics Reschedules Second Quarter 2023 Financial Results Conference Call
LITTLETON, Colo., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovati...
Vivos Therapeutics to Reschedule Second Quarter 2023 Financial Results Conference Call
LITTLETON, Colo., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovativ...
Vivos Therapeutics Schedules Release of Second Quarter 2023 Financial Results and Conference Call
LITTLETON, Colo., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovati...
Vivos Therapeutics Reports First Quarter 2023 Financial Results and Provides Operational Update
Revenue increased 6% Year-Over-Year; Operating Expenses Decreased 20% as Cost Cutting Initiatives Take Hold
Vivos Therapeutics Schedules Release of First Quarter 2023 Financial Results and Conference Call
LITTLETON, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovati...
Clinical Study Shows 92% of Patients Report Resolution of Migraine Headaches Using Vivos' POD® Appliance Treatment
Study Data Highlights New Vivos Treatment Option is Highly Effective in Treating Migraine Headaches, One of the World's Most Common Illnesses Study Data Highlights New Vivos Treatment Option is Highly...
Vivos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Operational Update
2022 and Early 2023 Accomplishments, Including Capital Raise, Cost Reductions and New Technology Acquisition, Set the Stage for Potential 2023 Revenue Growth
Vivos Therapeutics Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Conference Call
Call Scheduled for Today, Thursday, March 30, 2023 at 5:00 pm ET Call Scheduled for Today, Thursday, March 30, 2023 at 5:00 pm ET
Vivos Therapeutics to Participate in Fireside Chat at the 35th Annual ROTH Conference
LITTLETON, Colo., March 08, 2023 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (the “Company” or “Vivos”) (NASDAQ:VVOS), a medical device and technology company that delivers training and a full line o...
Vivos Therapeutics Expands Product Line and Revenue Potential with Acquisition of Product Rights and Patents from Advanced Facialdontics, LLC
Acquisition Adds Complementary, Lower Cost Products for Treating Conditions Associated with Obstructive Sleep Apnea Acquisition Adds Complementary, Lower Cost Products for Treating Conditions Associat...